New hope for tough leukemia cases: trial tests combo to overcome treatment resistance
NCT ID NCT07423104
Summary
This study is testing whether a combination of three drugs—cladribine, low-dose cytarabine, and venetoclax—can help control acute myeloid leukemia (AML) in adults whose cancer has returned or didn't respond to previous treatment containing venetoclax. The goal is to see if this regimen can achieve remission for patients who currently have very few options. About 24 participants will be enrolled to evaluate the treatment's effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.